Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Eton Pharmaceuticals (Nasdaq: ETON), a company focused on developing and commercializing treatments for rare diseases, has announced it will report its second quarter 2024 financial results on Thursday, August 8, 2024. The company will host a conference call and live audio webcast at 4:30 p.m. ET (3:30 p.m. CT) to discuss the results.
Management will take live questions from call participants and answer emailed questions from investors. Investors can email their questions to investorrelations@etonpharma.com. The live webcast will be accessible on Eton's website, with an archived version available for 30 days after the event.
Eton Pharmaceuticals (Nasdaq: ETON), un'azienda focalizzata nello sviluppo e nella commercializzazione di trattamenti per malattie rare, ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 giovedì 8 agosto 2024. L'azienda ospiterà una conference call e una diretta audio web alle 16:30 ET (15:30 CT) per discutere i risultati.
La direzione risponderà a domande in diretta dai partecipanti alla chiamata e alle domande inviate via email dagli investitori. Gli investitori possono inviare le loro domande a investorrelations@etonpharma.com. La diretta web sarà accessibile sul sito di Eton, con una versione registrata disponibile per 30 giorni dopo l'evento.
Eton Pharmaceuticals (Nasdaq: ETON), una empresa centrada en el desarrollo y comercialización de tratamientos para enfermedades raras, ha anunciado que informará sobre sus resultados financieros del segundo trimestre de 2024 el jueves 8 de agosto de 2024. La empresa llevará a cabo una llamada de conferencia y una transmisión de audio en vivo a las 4:30 p.m. ET (3:30 p.m. CT) para discutir los resultados.
La dirección responderá preguntas en vivo de los participantes de la llamada y también a preguntas enviadas por correo electrónico de los inversores. Los inversores pueden enviar sus preguntas a investorrelations@etonpharma.com. La transmisión en vivo estará disponible en el sitio web de Eton, y una versión grabada estará accesible durante 30 días después del evento.
Eton Pharmaceuticals(Nasdaq: ETON)는 희귀 질환 치료제를 개발하고 상용화하는 데 중점을 두고 있는 회사로, 2024년 2분기 재무 결과를 2024년 8월 8일 목요일에 발표할 것이라고 발표했습니다. 회사는 동부 시간 기준 오후 4:30 (중부 시간 기준 오후 3:30)에 결과를 논의하기 위한 전화 회의 및 생방송 오디오 웹캐스트를 개최할 예정입니다.
경영진은 전화에 참여하는 참가자들로부터 실시간 질문을 받고, 투자자들로부터 이메일로 받은 질문에도 답변할 것입니다. 투자자들은 investorrelations@etonpharma.com으로 질문을 보낼 수 있습니다. 생방송 웹캐스트는 Eton의 웹사이트에서 접속할 수 있으며, 행사 이후 30일 동안 아카이브 버전도 제공됩니다.
Eton Pharmaceuticals (Nasdaq: ETON), une entreprise axée sur le développement et la commercialisation de traitements pour les maladies rares, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le jeudi 8 août 2024. L'entreprise organisera une conférence téléphonique et un webinaire audio en direct à 16h30 ET (15h30 CT) pour discuter des résultats.
La direction prendra des questions en direct des participants à l’appel et répondra aux questions par e-mail des investisseurs. Les investisseurs peuvent envoyer leurs questions à investorrelations@etonpharma.com. Le webinaire en direct sera accessible sur le site web d'Eton, avec une version archivée disponible pendant 30 jours après l'événement.
Eton Pharmaceuticals (Nasdaq: ETON), ein Unternehmen, das sich auf die Entwicklung und Vermarktung von Behandlungen für seltene Krankheiten konzentriert, hat angekündigt, dass es am Donnerstag, den 8. August 2024 seine Finanzergebnisse für das zweite Quartal 2024 veröffentlichen wird. Das Unternehmen wird um 16:30 Uhr ET (15:30 Uhr CT) eine Telefonkonferenz und einen Live-Audio-Webcast abhalten, um die Ergebnisse zu besprechen.
Die Geschäftsleitung wird live Fragen von den Teilnehmern der Telefonkonferenz beantworten und E-Mail-Fragen von Investoren. Investoren können ihre Fragen an investorrelations@etonpharma.com senden. Der Live-Webcast wird auf der Website von Eton zugänglich sein und eine archivierte Version wird 30 Tage nach der Veranstaltung verfügbar sein.
- None.
- None.
DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
| Dial in* (Audio Only) | Click Here |
| Webcast: | Click Here |
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
*Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals
FAQ
When will Eton Pharmaceuticals (ETON) report its Q2 2024 financial results?
What time is Eton Pharmaceuticals' (ETON) Q2 2024 earnings call scheduled for?
How can investors participate in Eton Pharmaceuticals' (ETON) Q2 2024 earnings call?
Where can I find the webcast for Eton Pharmaceuticals' (ETON) Q2 2024 earnings call?
